Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akcea Therapeutics Inc.

Division of Ionis Pharmaceuticals Inc.
www.akceatx.com

Latest From Akcea Therapeutics Inc.

Regeneron’s Cholesterol Drug Aces Phase III, Teeing Up US FIling

The trial linked ANGPTL3 antibody evinacumab to a steep decline in LDL cholesterol in patients with homozygous familial hypercholesterolemia, setting Regeneron up to file for US FDA approval next year.

Clinical Trials Companies

After IPO, BridgeBio Looks To Tuck Eidos Back Into Its Flock

Is Eidos a goose that could lay a golden egg? BridgeBio wants to own it all, instead of two-thirds, in case its subsidiary's lead program in TTR amyloidosis succeeds in Phase III.

Deals M & A

A Win For Alnylam In England As NICE Reverses Onpattro Rejection

Health technology appraisal body NICE now says that Alnylam's innovative gene silencing drug is value for money for the treatment of the rare disease, hereditary transthyretin-related amyloidosis.

Reimbursement United Kingdom

New EU Approvals

The Pink Sheet’s list of EU centralized approvals of new active substances now includes two new products, one of which is bluebird bio's genetically modified product for treating beta-thalassemia, Zynteglo. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).

Approvals Europe
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Alias(es)
  • 1662524
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ionis Pharmaceuticals Inc.
  • Senior Management
  • Paula Soteropoulos, CEO
    Michael MacLean, CFO
    Jeffrey M Goldberg , COO
    Louis St. L O’Dea, MD, CMO
    Sarah Boyce, Pres.
  • Contact Info
  • Akcea Therapeutics Inc.
    Phone: (617) 207-0202
    55 Cambridge Parkway
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register